AbbVie
ABBV
2,063 hedge funds and large institutions have $95.6B invested in AbbVie in 2018 Q4 according to their latest regulatory filings, with 222 funds opening new positions, 681 increasing their positions, 896 reducing their positions, and 100 closing their positions.
122% more first-time investments, than exits
New positions opened: 222 | Existing positions closed: 100
44% more funds holding in top 10
Funds holding in top 10: 103 → 148 (+45)
5% more funds holding
Funds holding: 1,957 → 2,063 (+106)
6% less call options, than puts
Call options by funds: $1.13B | Put options by funds: $1.2B
1.01% less ownership
Funds ownership: 70.57% → 69.56% (-1%)
5% less capital invested
Capital invested by funds: $101B → $95.6B (-$5.48B)
24% less repeat investments, than reductions
Existing positions increased: 681 | Existing positions reduced: 896
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
+$366M |
| 2 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$238M |
| 3 |
Capital International Investors
Los Angeles,
California
|
+$178M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$160M |
| 5 |
Wells Fargo
San Francisco,
California
|
+$112M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
-$531M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$408M |
| 3 |
Capital Research Global Investors
Los Angeles,
California
|
-$226M |
| 4 |
Canada Pension Plan Investment Board
Toronto Ontario,
Ontario, Canada
|
-$200M |
| 5 |
Barclays
London,
United Kingdom
|
-$188M |
ABBV Hedge Fund Activity: Q4 2018 in Review
2,063 of the 4,489 institutional investors tracked by Wall St. Rank reported a position in AbbVie (ABBV) for Q4 2018, worth a combined $95.6B — down 5.4% from $101B a quarter earlier.
Buyers outnumbered sellers: 222 funds opened new ABBV positions and 100 closed out — a net gain of 122 holders — while 681 added to existing stakes and 896 trimmed.
The largest buyer was Janus Henderson Group, adding an estimated $366M. The largest seller was Capital World Investors, cutting an estimated $531M.
- 2,063 institutional investors held AbbVie (ABBV) as of Q4 2018, up from 1,957 in Q3 2018.
- Funds reported $95.6B of AbbVie stock for Q4 2018, down 5.4% quarter-over-quarter.
- 222 funds opened new AbbVie positions in Q4 2018 and 100 closed out, a net change of +122 holders.
- The largest AbbVie buyer in Q4 2018 was Janus Henderson Group, an estimated $366M added.
- The largest AbbVie seller in Q4 2018 was Capital World Investors, an estimated $531M sold.
Based on aggregated 13F filings for Q4 2018.